Novavax on Monday introduced it’s starting a part three trial of its coronavirus vaccine, changing into the fifth firm to enter a late-stage trial in the US.
Whereas two different coronavirus vaccines, from Pfizer and Moderna, have already been licensed within the U.S., the addition of extra choices would make extra doses obtainable and velocity the vaccination marketing campaign.
The Novavax vaccine, which makes use of a extra conventional vaccine expertise than Pfizer and Moderna, additionally has the benefit of not requiring ultra-cold storage, making it simpler to distribute.
Novavax, with backing from the Trump administration’s Operation Warp Velocity, is enrolling as much as 30,000 volunteers at 115 websites throughout the U.S. and Mexico within the medical trial.
A trial has already begun in the UK. Novavax had supposed to start its U.S. trial earlier, however delayed the beginning due to manufacturing issues.
“The launch of this examine—the fifth investigational COVID-19 vaccine candidate to be examined in a Part three trial in the US—demonstrates our resolve to finish the pandemic by means of improvement of a number of protected and efficient vaccines,” stated Anthony FauciAnthony FauciTSA screened 1.1M vacationers the day after Christmas Saudi Arabia to permit outgoing worldwide flights for international nationals December deadliest month of COVID-19 pandemic MORE, the federal government’s high infectious illnesses professional.
Surging virus instances throughout the nation can truly assist velocity up the trial, given that instances of the virus within the group receiving the placebo will accrue sooner.
“Trial websites have been chosen in places the place transmission charges are at the moment excessive, to speed up the buildup of optimistic instances that might present efficacy,” Novavax stated in a press launch.